Preserflo Microshunt
Edited by:
Last updated: August 5th, 2022
Summary of Evidence
Efficacy
Sustained reductions in mean IOP and medications were observed at 5 years post-PRESERFLO MicroShunt implantation. There were no reports of long-term sight-threatening AEs and a low rate of postoperative interventions.{Batlle JF, Corona A, Albuquerque R. Long-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study. J Glaucoma. 2021 Mar 1;30(3):281-286.}
Evidence
1. Background
2. Safety and efficacy
2.1 Comparative effectiveness
2.1.1 PRESERFLO alone
2.1.2 PRESERFLO vs XEN
References
Comments
Subscribe
Login
0 Comments